Removal of cell surface SORT1 by anti-SORT1 mAb may block BDNF signaling and anti-SORT1 mAb may be beneficial for the treatment of neuropathic pain, a major clinical challenge resulting from peripheral nerve trauma or disease. The gene discussed is BDNF; the disease is neuropathic pain.